MedTrace Logo

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

NCT00649922 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2008-04-01

No results posted yet for this study

Summary

To evaluate the immunogeneicity of the Influenza virus and standard 23-valent pneumococcal virus in subject with RA receiving adalimumab or placebo

Conditions

Interventions

BIOLOGICAL

adalimumab

80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29

BIOLOGICAL

placebo

2 injections Day 1, 1 injection Days 15 and 29

BIOLOGICAL

adalimumab

40 mg adalimumab every other week

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2004-12-31
Completion
2005-02-28

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00649922 on ClinicalTrials.gov